Protective effects of inhibitors of nitric oxide synthase in immune complex‐induced vasculitis by Mulligan, M.S. et al.
Br. J. PharmacoL. (1992), 107, 1159-1162
Protective effects of inhibitors of nitric oxide synthase in
immune complex-induced vasculitis
M.S. Mulligan, ',*S. Moncada & P.A. Ward
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, U.S.A. and *Wellcome
Research Laboratories, Langley Court, South Eden Park Road, Beckenham, Kent BR3 3BS
1 The ability of analogues of L-arginine (N-iminoethyl-L-ornithine (L-NIO), N0-monomethyl-L-arginine
(L-NMMA), N0-nitro-L-arginine methyl ester (L-NAME) and NG-nitro-L-arginine (L-NNA)) to protect
against inflammatory injury induced by activated neutrophils was investigated in rats following intra-
dermal or intrapulmonary deposition of immune complexes.
2 The descending order of potency for protective effects of these analogues was: L-NIO> L-NMMA>
L-NNA = L-NAME. The approximate IC5i value for L-NIO in the dermal vasculitis model was 65 0tM.
For all other compounds, the ICso values were >5 mM.
3 The protective effect of L-NIO in the skin was reversed in a dose-dependent manner by the presence
of L-arginine, but not by D-arginine. L-Arginine also reversed the protective effects of L-NIO in immune
complex-induced lung injury.
4 The protective effects of L-NIO were not associated with reductions in neutrophil accumulation, as
measured by extraction from tissues of myeloperoxidase.
5 These data demonstrate that L-NIO has the most potent protective effects against immune complex-
induced vascular injury induced by activated macrophages. Furthermore, they indicate that this injury is
dependent upon the generation of nitric oxide.
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Introduction
Phagocytic cells, including neutrophils as well as macro-
phages, generate nitric oxide (NO) via an NO synthase that is
inducible by immunological stimuli such as endotoxin (LPS)
and various cytokines (Hibbs et al., 1988; Marletta et al.,
1988; McCall et al., 1989; Schmidt et al., 1989; Stuehr &
Nathan, 1989; Wright et al., 1989; Billiar et al., 1990; Curran
et al., 1990). Generation of NO by macrophages has been
showed to kill tumour cells due to the inactivation of iron-
sulphur centres of mitochondrial enzymes (Drapier & Hibbs,
1986; Hibbs et al., 1987; 1988). The broader role of NO in
the inflammatory response is not well established, although
the reactivity of NO or its potential conversion product,
peroxynitrite anion, with sulphydryl groups indicates the pos-
sibility of cellular biochemical targets whose alteration would
put tissue at risk of injury.
Recently, it has been demonstrated that IgG immune com-
plex-initiated injury of rat lung is greatly attenuated by the
presence of the L-arginine analogue, NG-monomethyl-L-
arginine (L-NMMA) (Mulligan et al., 1991). The protective
effects of L-NMMA were not associated with a reduced
influx of neutrophils into lungs, suggesting that toxic meta-
bolites of L-arginine may be responsible for the inflammatory
injury, which is known to depend upon the recruitment and
participation of neutrophils (Johnson & Ward, 1979). Since
N-iminoethyl-L-ornithine (L-NIO) has recently been described
as a highly potent inhibitor of phagocytic cell NO synthase
(McCall et al., 1991), this compound was tested for its ability
to protect against immune complex-induced vascular injury
in rats. In addition, the effects of L-NIO were compared with
those of other L-arginine analogues, namely, L-NMMA, NG-
nitro-L-arginine (L-NNA) and its methyl ester (L-NAME).
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Methods
Models of immune complex-induced alveolitis and
dermal vasculitis
With adult male (300 g) specific pathogen-free Long-Evans
rats (Charles River Breeding Laboratories), immune complex
reactions were induced in lung and skin by the intratracheal
(2.5 mg of antibody in 300,l) or intradermal (0.42 mg of
antibody in 50 Itl) injection of polyclonal rabbit IgG anti-
body to bovine serum albumen (anti-BSA) followed by the
intravenous injection of 10 mg BSA containing trace amounts
of [1251]-BSA. Tissue injury was assessed at 4 h by the in-
crease in vascular permeability. Permeability values were
defined as the ratio of 251I-labelled BSA in lung or skin sites
to the amount present in 1.0 ml blood obtained from the
inferior vena cava at the time of death. Previously, we report-
ed that BSA-anti-BSA immune complexes produced in
untreated positive control rats lung and dermal vascular
permeability values of approximately 0.46 (Mulligan et al.,
1991). In the current studies a new batch of anti-BSA was
employed, giving the indicated permeability values which
were approximately double those recorded early. Accord-
ingly, computed percentages of protein were different from
those observed earlier with the different batch of antibody
which was less injurious.
Tissue myeloperoxidase (MPO) content
A standard reference curve was first established by measuring
MPO in lungs and skin sites that had been injected with
known numbers of neutrophils. Lung and skin sites were
extracted by homogenization and sonication procedures that
have been previously described (Mulligan et al., 1991). MPO
activity in supernatant fluids was measured by the change in
optical density (at 460 nm) resulting from decomposition of
H202 in the presence of o-dianisidine.
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Statistical analysis
The data were analyzed by one-way analysis of variance
(ANOVA). Additional comparisons were made between indi-
vidual groups by the use of paired or unpaired Student's t
tests. All values were expressed as mean ± s.e.mean unless
otherwise indicated. Statistical significance was defined as
P< 0.05.
Materials
L-NIO and L-NNA were provided by Wellcome Research
Laboratories (Beckenham, Kent) while L-NAME and L-
NMMA were from Cal Biochem (La Jolla, California,
U.S.A.). Rabbit polyclonal IgG antibody to bovine serum
albumin (anti-BSA) was from Organon Teknicka (West-
chester, PA, U.S.A.).
Results
Protective effects of L-arginine analogues in dermal
vascular injury
Immune complex deposition was induced by the intra-dermal
injection of anti-BSA and the intravenous injection of BSA.
The resulting vascular injury was measured 4 h later by
leakage of ['25I]-albumen into skin sites. In the negative con-
trols (omission of intravenously injected BSA) and positive
controls, the permeability values were 0.07 ± 0.01 and 0.81 ±
0.03, respectively. When used, the L-arginine analogues were
mixed with the anti-BSA preparations immediately prior to
intradermal injection. Concentrations of the analogues em-
ployed were: 0.01, 0.1, 0.5, 1.0 and 5.0mm. The data in
Figure 1 show the comparative abilities of the four analogues
of L-arginine to reduce immune complex-induced vascular
injury, as measured by changes in vascular permeability. The
most effective compound was L-NIO, which caused a marked
reduction in the increase in vascular permeability. L-NIO had
an estimated IC50 of 65 JM. At 1.0 mM, L-NMMA reduced
the permeability change by 32%, but this was not further
reduced with 5 mM L-NMMA. L-NNA and L-NAME were
much less potent; at 5 mM, the protective effects were only
19% and 16%, respectively. Thus, the rank order of protec-
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tive effects for these L-arginine analogues in immune com-
plex-induced dermal vascular injury is: L-NIO> L-NMMA>
L-NNA = L-NAME.
Ability of L-arginine to reverse protective effects of
L-NIO
In the same model of immune complex-induced dermal vas-
cular damage, the presence of 1.0 mM L-NIO in the anti-BSA
preparation resulted in a fall in the permeability index from
the positive control (absence of L-NIO), from 0.81 ± 0.03 to
0.46 ± 0.02, a 47% reduction (P <0.001) in the permeability
index. As L-arginine was added in increasing concentrations
to anti-BSA preparations which contained 1.0 mM L-NIO,
the reductions (reversals) in vascular permeability reflecting
the protective effects of L-NIO were correspondingly revers-
ed: with 0.1, 0.5, 1.0, 5.0 and 10mM L-arginine, the perme-
ability values were: 0.55 ± 0.03 (35% reduction, P = 0.002);
0.66 ± 0.04 (20% reduction, P = 0.049); 0.74 ± 0.02 (9%
reduction, P = NS); 0.81 ± 0.02 (0% reduction, P = NS), and
0.93 ± 0.02 (16% increase in permeability compared to the
positive control, P = NS), respectively. The presence of
1.0mM D-arginine with 1.0mM L-NIO did not reverse the
protective effects of the latter (data not shown).
Protective effects of L-NIO in immune complex induced-
dermal vascular injury: effects on tissue MPO content
These experiments were carried out with positive and nega-
tive (omission of intravenously injected BSA) controls and
extraction of skin sites at 4 h for MPO following deposition
of immune complexes. In a comparison series of skin sites
injected with anti-BSA containing 1.0 mM L-NIO alone or in
combination with 1 mM D-arginine, or with 0.1, 0.5, 1.0, 5.0
or 10mM L-arginine, a protocol similar to that described in
Figure 2 was employed. The negative and positive controls
showed an MPO content of 0.08 ± 0.01 and 0.39 ± 0.02,
respectively. The range of MPO content in all L-NIO-injected
skin sites was 0.37 ± 0.02 to 0.41 ± 0.02, none of which was
statistically significantly different from the positive reference
control value (data not shown). Thus, the protective effects
of L-NIO in immune complex-induced vasculitis are not
associated with a blocking of the recruitment of neutrophils
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Figure 1 The effects of various concentrations of L-NIO (0), L-
NMMA (A), L-NNA (0), and L-NAME (@) on vascular injury
(measured by leakage of ['251l-albumen) in dermal skin sites contain-
ing IgG immune complexes. Compounds were added to the anti-BSA
immediately prior to intradermal injection. All reactions were
assessed 4 h after initiation of immune complex deposition. For each
data point, n = 8. For statistical purposes, comparisons were made
with skin sites containing immune complexes in the absence of an
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Figure 2 Reversal of protective effects of 1.0 nM L-NIO by
copresence of L-arginine (0) which was added in a range of concen-
trations (0.01-10 nM) to the anti-BSA prior to intradermal injection.
The reference positive value (for vascular permeability) was
0.81 ± 0.03 while the negative control (absence of intravenously
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Protective effects ofL-NIO in immune complex-induced
alveolitis
IgG immune complex deposition was also induced in rat lung
by the intratracheal instillation of anti-BSA (1.5 mg in a total
volume of 300 pil) in the presence or absence of 5.0 mM
L-NMMA or 5.0 mM L-NIO and the effects on vascular
injury assessed according to the increase in lung vascular
permeability. This lower dose of antibody was employed in
order to accentuate differences in the protective effects of the
L-arginine antagonists. For the experiments shown in Figure
3, the values for the negative (omission of intravenously
injected BSA) and positive control groups were 0.16 ± 0.01
and 0.52 ± 0.02, respectively. When the negative control
value was subtracted from the values of the positive control
groups (treated or untreated with L-NMMA or L-NIO) and
the ratios computed, 5.0 mM L-NMMA caused a 50% reduc-
tion (P= 0.009) in intensity of lung injury as reflected by
change in vascular permeability while L-NIO caused an 82%
reduction (P = 0.002) in lung injury (a fall in the permeability
to 0.22 ± 0.01). L-NIO had statistically greater protective
effects when compared to L-NMMA (P = 0.021), in which
case the permeability value was 0.33 ± 0.01.
Additional studies on the effects of L-arginine analogues on
the intensity of lung injury (as measured by permeability
changes) were performed, as shown in Figure 4. For these
experiments a concentration of 2.5 mg anti-BSA was employ-
ed. The negative and positive control values were 0.16 ± 0.01
and 0.75 ± 0.03, respectively. All results were compared to
the positive control values (anti-BSA in the absence of any
analogue of L-arginine). The presence of 5.0 mM L-NMMA,
L-NAME, L-NIO, L-NIO + D-arginine, and L-NIO + L-argin-
ine was associated with permeability values of 0.46 ± 0.02
(reduction of 49%, P = 0.002); 0.60 ± 0.03 (reduction of
25%, P = 0.027); 0.43 ± 0.02 (reduction of 54%, P = 0.001);
0.44 ± 0.01 (reduction of 53%, P= 0.001); and 0.84 ± 0.02
(intensification of injury by 15%, P = NS), respectively.
Thus, L-NIO is a potent inhibitor of vascular injury develop-
ing in lung following deposition of IgG immune complexes
and its protective effects are reversed by L-arginine but not
by D-arginine. In this experiment there are not sufficient data
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Figure 3 Protective effects (assessed by changes in vascular
permeability) of L-NIO and L-NMMA on immune complex-induced
pulmonary vascular injury. When employed, 5 mM L-NMMA or
L-NIO was added to the anti-BSA preparation prior to its intra-
tracheal administration. Reactions were measured 4 h after deposi-
tion of IgG immune complexes. All comparisons were to the positive




















Figure 4 Ability of various analogues of L-arginine to reduce lung
vascular injury (as assessed by increased vascular permeability) fol-
lowing intrapulmonary deposition of IgG immune complexes. All
compounds employed were used at 5 nm concentrations. Statistical
comparisions were made with the positive control group and repre-
sent significance of reductions in vascular permeability for each
vertical column, n = 4. For abbreviations, see text.
When lungs from animals undergoing immune complex
deposition were compared for MPO content to those lungs in
which anti-BSA also contained L-NIO or L-NMMA, no
difference was found in the lung content of MPO (data not
shown), confirming the pattern found for the protective
effects of analogues of L-arginine in the skin (described
above).
Discussion
The ability of L-arginine analogues to reduce evidence of IgG
immune complex-induced dermal vascular injury in rats
reveals the rank order of potency: L-NIO> L-NMMA> L-
NNA = L-NAME, which is in remarkable agreement with
the in vitro effects of these compounds on their ability to
block NO synthase in rat peritoneal neutrophils or in J774
cells, whether measured by interference with platelet aggrega-
tion or by direct measurement of NO formation in cytosolic
fractions of cells (McCall et al., 1991). The estimated IC50
value (65 I.M) for the in vivo protective effects of L-NIO in
skin is much higher than the value obtained in vitro (0.8 gM),
but this is readily explained by the fact that the total volume
of intradermally injected material is 50 1d, which becomes
rapidly diluted as the permeability changes begin to occur in
the developing acute inflammatory reaction. Since the mini-
mal volume increase in the positive control sites is nearly 16
fold (to 800 pl) above the negative control value and the
outflow, chiefly through efferent lymphatic channels, has not
been measured, the effective local in vivo concentration can-
not be accurately computed but would probably be reduced
many fold below the initial concentration, perhaps to
<31tM. A key factor in the efficacy of L-NIO when com-
pared to the other analogues of L-arginine appears to be the
more rapid onset in its inhibitory effects when added to the
phagocytic cells (10 min versus 20-60 min) and the irreversi-
ble effect of L-NIO as compared to the other analogues
(McCall et al., 1991).
These data indicate that L-arginine analogues such as L-
NIO may be useful in preventing tissue damage which is
generated by toxic products of activated neutrophils (and
macrophages). In the rat dermal and lung models of immune
complex-induced vascular injury, neutrophils have long been
shown to be key participants in the events leading to injury
(Johnson & Ward, 1979; Warren et al., 1990). The protective
effects of antioxidants such as superoxide dismutase (SOD)
and catalase have led to the suggestion that toxic metabolites
Uuv-V I", , f ,,.
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of oxygen may be key initiators of injury (Johnson & Ward,
1981). The protective effects of SOD are complicated by the
fact that this compound has time-limited protective effects
(2 h) in the immune complex models of injury (Johnson &
Ward, 1981), which may be related to the generation of
02-dependent chemotactic lipids (Von Zabern et al., 1987;
Vogt et al., 1989). The recent finding that L-NMMA has
significant protective effects in immune complex-induced
injury in rat lung and skin (Mulligan et al., 1991) has caused
a re-evaluation of the pathways leading to injury and has
emphasized that L-arginine, or presumably its metabolic pro-
ducts, are injurious, perhaps through the generation of per-
oxynitrite anion or the hydroxyl radical (Beckman et al.,
1990). The most remarkable finding in the earlier study
(Mulligan et al., 1991) and in the current one is that the
protective effects are not associated with a reduced tissue
accumulation of neutrophils, implying that the protective
effects of L-NIO and L-NMMA are not attributable to an
interference with neutrophil emigration from the vasculature.
The current studies indicate that compounds capable of
blocking NO formation may have significant protective
effects against injury in a variety of human inflammatory
diseases.
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